AIVITA Biomedical is an immuno-oncology company designing personalized vaccines that target the seed of all cancers: tumor-initiating cells. Founded in 2016 by pioneers in the stem cell industry, AIVITA Biomedical utilizes its expertise in stem cell growth and directed, high-purity differentiation to enable safe, efficient and economical manufacturing systems which support its commercial products and therapeutic pipeline.
AIVITA’s lead focus is on a patient-specific immunotherapy for the treatment of advanced cancers. The treatment, autologous dendritic cells loaded with autologous tumor cells, directs the patient’s own immune system to seek out and destroy the very cells responsible for the growth and spread of the disease. AIVITA takes a unique pan-antigenic approach—targeting all neoantigens in tumor-initiating cells, rather than a select few — allowing the treatments to overcome cancer’s tendency to mutate over time. Based on clinical trial results showing tremendous promise in eradicating tumors without harmful side effects, the technology is currently being commercialized for melanoma in Japan, and is the subject of two US-based Phase 2 clinical trials for ovarian cancer and glioblastoma. The company is also developing an immune monitoring technology to be used in conjunction with its immunotherapy approach. The technique uses biomarker identification to provide physicians with an accurate prediction of how the patient will respond to treatment.
AIVITA Biomedical is also leveraging it’s proprietary capabilities and know-how to develop innovative commercial products in additional fields, beginning with an anti-aging skincare technology containing more skin-relevant active ingredients than any other product. The clinically proven technology includes growth factors captured from skin stem cells, the very cells responsible for the maintenance and renewal of young skin. All proceeds from the sale of AIVITA’s skincare products support the treatment of ovarian and brain cancer patients. The company is also advancing grant-funded research to apply its expertise in vision loss.